Adecatumumab
Adecatumumab
Adecatumumab (pronounced: ad-eh-kah-too-moo-mab) is a monoclonal antibody designed for the treatment of cancer. It was developed by Merck KGaA.
Etymology
The name "Adecatumumab" is derived from the International Nonproprietary Naming (INN) system for pharmaceutical substances. The "-mab" suffix indicates that it is a monoclonal antibody, while the prefix "Adecatu-" does not have a specific meaning and is used for unique identification.
Mechanism of Action
Adecatumumab works by binding to the EpCAM (Epithelial Cell Adhesion Molecule), a protein that is overexpressed in many types of cancer. By binding to EpCAM, Adecatumumab can inhibit the growth and spread of cancer cells.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- EpCAM: A protein that is overexpressed in many types of cancer and is the target of Adecatumumab.
- Merck KGaA: A German multinational pharmaceutical, chemical and life sciences company headquartered in Darmstadt, with around 50,000 employees in around 70 countries. Merck KGaA developed Adecatumumab.
External links
- Medical encyclopedia article on Adecatumumab
- Wikipedia's article - Adecatumumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski